Disclosures

Al B. Benson III, MD
Site Editor for Colorectal Cancer 

Received clinical research support/data safety monitoring board from Advanced Accelerator Applications SA, Alchemia, Astellas, Aveo, Bayer HealthCare, EMD Serono, Genentech, Inc., Gilead, Infinity, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.

Served on scientific advisory board or as a consultant or expert witness for Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, EMD Serono, Exelixis Inc., Genentech, Inc., Genomic Health, Inc., ImClone Systems Incorporated, Merck & Co., Inc., National Cancer Institute, Oncosil Medical, sanofi-aventis U.S., Spectrum Pharmaceutics, and Taiho Pharmaceuticals Co., Ltd.

Daniel G. Coit, MD
Site Editor for Melanoma 

Reported no conflicts of interest.

David S. Ettinger, MD

Site Editor for Non–Small Cell Lung Cancer 

Received clinical research support/data safety monitoring board from Golden Biotechnology.

Served on scientific advisory board or as a consultant or expert witness for AbbVie, BeyondSpring Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono, Genentech, Inc., Guardant Health, Inc., Helsinn Therapeutics (US), Inc., Herron Therapeutics, McGivney Global Consultants, and Trovagene, Inc.

William J. Gradishar, MD
Site Editor for Breast Cancer 

Received clinical research support/data safety monitoring board from Genentech, Inc. and Pfizer, Inc.

Served on scientific advisory board or as a consultant or expert witness for Eisai, Inc. and Genentech, Inc.

Shaji K. Kumar, MD

Site Editor for Multiple Myeloma

Received clinical research support/data safety monitoring board from Abbott Laboratories, Amgen, Inc., Celgene Corporation, Janssen Pharmaceutical Products, LP, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Oncopeptides, Roche Laboratories, Inc., Sanofi-aventis U.S., and Takeda Pharmaceuticals North America, Inc.

Served on scientific advisory board or as a consultant or expert witness for Abbott Laboratories, Amgen Inc., Janssen Pharmaceutical Products, LP, Karyopharm, Kite, Merck & Co., Inc., Skyline Diagnostics, and Takeda Pharmaceuticals North America, Inc.

Michael J. Mauro, MD

Co-Site Editor for Chronic Myeloid Leukemia

Received clinical research support/data safety monitoring board as principal investigator for Novartis Pharmaceuticals Corporation.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals North America, Inc., and Pfizer, Inc.

Robert J. Motzer, MD

Site Editor for Kidney Cancer 

Received clinical research support/data safety monitoring board from Bristol-Myers Squibb Company, Exelixis Inc., Genentech, Inc., Novartis Pharmaceuticals Corporation, and Roche Laboratories, Inc.

Served on scientific advisory board or as a consultant or expert witness for Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.

Michael A. Postow, MD

Co-Site Editor for Melanoma

Received clinical research support/data safety monitoring board from Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Array BioPharma, Infinity Pharmaceuticals, and Rgenix, Inc.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Array BioPharma, Merck & Co., Inc., Incyte Corporation, and Newlink Genetics.

Jerald P. Radich, MD

Site Editor for Chronic Myeloid Leukemia 

Received clinical research support/data safety monitoring board from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Novartis Pharmaceuticals Corporation, and Seattle Genetics.

Served on scientific advisory board or as a consultant or expert witness for ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb Company. Gilead Sciences, Novartis Pharmaceuticals Corporation, and Seattle Genetics.

Ursula A. Matulonis, MD

Site Editor for Ovarian Cancer 

Served on scientific advisory board or as a consultant or expert witness for 2X Oncology, AstraZeneca Pharmaceuticals LP, Clovis, Fujifilm, Geneos, Myriad Genetic Laboratories, Inc., Syndax, and Tesaro.

Writers:

Melissa Eng

Serves as a Research Coordinator at the Northwell Health Clinical Trials Office.

The following individuals contributing to JNCCN 360 reported no relevant conflicts of interest: Meg Barbor, MPH; Sarah Campen, PharmD; Joseph Cupolo; Cordi Craig; Celeste L. Dixon; Laura Entis; Joseph Fanelli; Andrew Goldstein; Emir Hadzic, PhD; Sarah Jackson; Julian Lim; Susan London; Margie Miller; Susan Reckling; and Sara Tewksbury.